LEUKEMIA, MYELOID, ACUTE

This early-stage study tests the safety of a new drug called ziftomenib when combined with standard chemotherapy for people whose acute myeloid leukemia (AML) has returned or not responded to treatment. The study includes adults with specific genetic changes (NPM1 mutation or KMT…

This study tests whether two drugs, azacitidine and chidamide, can safely help control high-risk acute myeloid leukemia (AML) after a stem cell transplant. About 20 adults aged 18 to 60 will take these drugs as maintenance therapy. The goal is to see if the combination reduces th…

This study tests whether adding the experimental drug bleximenib to standard medicines (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. It includes 600 adults aged 18 and older who are new…

This study tests whether adding the experimental drug cusatuzumab to the standard two-drug therapy (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) live longer. About 120 people who cannot receive intensive chemotherapy will take part. T…

This trial tests a new treatment for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack leukemia cells. …

This early-stage trial tests a new daily pill, BH-30236, for adults with acute myeloid leukemia (AML) or a high-risk pre-leukemia condition (MDS) that has returned or not responded to prior treatments. The study will first find the safest dose, then test it alone or with another …

This study tests a personalized cell therapy called Orca-T for 80 adults with acute myeloid leukemia or myelodysplastic syndrome. Participants receive a stem cell transplant with specially processed donor cells designed to reduce complications like graft-versus-host disease. The …

This early-phase study tests a new drug, JNJ-90189892, in people with acute myeloid leukemia or myelodysplastic neoplasms that returned or didn't respond to treatment. The main goal is to find a safe dose and check for side effects. About 155 adults will take part, and later part…

This study tests a combination of three drugs (venetoclax, chidamide, and azacitidine) in adults whose acute myeloid leukemia has returned or not responded to prior treatment. The goal is to see if this mix can safely achieve remission. About 30 participants will receive the trea…

This study tests a new two-drug combination for adults with acute myeloid leukemia that has come back or not responded to prior treatments. The drugs, DFP-10917 and venetoclax, are given together to try to control the cancer. About 39 participants will receive the treatment to se…

This study tests an experimental drug called enzomenib in about 600 people with acute leukemia and certain other blood cancers. The goal is to find the safest dose and see if the drug can shrink or control the cancer. Participants must have cancers that came back or did not respo…

This study explores how a person's genetic makeup influences side effects and response to two common leukemia drugs (azacitidine and venetoclax). Researchers will enroll 50 adults newly diagnosed with acute myeloid leukemia (AML) and track side effects like infections and low blo…